Sun Pharmaceutical Industries today announced that it has received the Establishment Inspection Report (EIR) from the US FDA for the inspection conducted at its Halol facility (Gujarat, India) during the period February 12-23, 2018. The agency concluded that the inspection is now closed and the issues contained in the Warning Letter issued in December 2015 have been addressed.

Dilip Shanghvi, Managing Director, Sun Pharma said, ''This is an important development for Sun Pharma. We remain committed to following the highest levels of quality and 24x7 cGMP compliance at all our manufacturing facilities globally.'' 

Shares of the company gained Rs 5.5, or 1.03%, to settle at Rs 540.50. The total volume of shares traded was 507,842 at the BSE (Tuesday).